|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Aquila_Biolabs_Gmb_H
gptkb:Aderis_Pharmaceuticals
various biotech firms
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:business_model
|
biopharmaceutical development
|
|
gptkbp:ceo
|
gptkb:Peter_Llewellyn-Davies
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
multiple ongoing trials
MDG1011
Phase I, II, and III
advanced stages
multiple phases conducted
various international sites
MDG1021
MDG1031
|
|
gptkbp:collaboration
|
gptkb:University_of_Munich
enhance research capabilities
|
|
gptkbp:collaborations
|
gptkb:Max_Planck_Institute
gptkb:German_Cancer_Research_Center
gptkb:Heidelberg_University
academic institutions
joint ventures with universities
|
|
gptkbp:community_engagement
|
active in local communities
|
|
gptkbp:employees
|
over 100
~100 (2021)
|
|
gptkbp:financial_performance
|
monitored regularly
|
|
gptkbp:financial_reports
|
published quarterly
|
|
gptkbp:focus
|
gptkb:immunotherapy
|
|
gptkbp:founded
|
gptkb:1994
|
|
gptkbp:funding
|
secured from various sources
|
|
gptkbp:future_plans
|
expand into new markets
|
|
gptkbp:has_advisory_board
|
composed of experts
|
|
gptkbp:head_of_state
|
active in seeking partnerships
|
|
gptkbp:headquarters
|
gptkb:Planegg,_Germany
gptkb:Martinsried,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Medi Gene AG
|
|
gptkbp:instruction_set
|
multiple drug candidates
|
|
gptkbp:invention
|
immunotherapy patents
numerous granted patents
biologics patents
protected by patents.
|
|
gptkbp:investment
|
transparent communication
biopharmaceutical research
institutional and private investors
diverse group
R& D investments
|
|
gptkbp:is_a_platform_for
|
proprietary technologies
|
|
gptkbp:key_people
|
gptkb:Dr._Frank_Mathias
|
|
gptkbp:location
|
gptkb:Germany
|
|
gptkbp:market
|
gptkb:Europe
gptkb:Germany
gptkb:United_States
|
|
gptkbp:market_cap
|
varies with stock performance
|
|
gptkbp:market_position
|
growing presence in Europe
|
|
gptkbp:marketing_strategy
|
focus on niche markets
|
|
gptkbp:number_of_employees
|
approximately 100
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:Roche_Holding_AG
gptkb:Merck_KGa_A
gptkb:Novartis_AG
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Eisai_Co.,_Ltd.
gptkb:Pfizer_Inc.
gptkb:Sanofi_S._A.
|
|
gptkbp:partnerships
|
various pharmaceutical companies
|
|
gptkbp:product
|
gptkb:Endo_TAG-1
gptkb:Onco_One
ongoing innovation
T cell therapy
T cell receptor therapy
DC vaccine
|
|
gptkbp:products
|
T cell therapies
|
|
gptkbp:publications
|
numerous publications
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:European_Medicines_Agency
adheres to regulations
various approvals
|
|
gptkbp:research_areas
|
oncology
autoimmune diseases
focused on innovative therapies
|
|
gptkbp:research_focus
|
gptkb:cancer_treatment
cell-based therapies
|
|
gptkbp:revenue
|
varies annually
€20 million (2020)
|
|
gptkbp:social_responsibility
|
engaged in CSR initiatives
|
|
gptkbp:stock_symbol
|
MDG1
|
|
gptkbp:strategic_goals
|
expand product portfolio
|
|
gptkbp:subsidiaries
|
gptkb:Medi_Gene_Inc.
|
|
gptkbp:subsidiary
|
gptkb:Medi_Gene_Inc.
|
|
gptkbp:sustainability_practices
|
environmentally conscious practices
|
|
gptkbp:technology
|
T cell receptor technology
antigen-specific immunotherapy
|
|
gptkbp:therapeutic_indications
|
multiple cancer types
|
|
gptkbp:traded_on
|
gptkb:Frankfurt_Stock_Exchange
|
|
gptkbp:treatment
|
measured in trials
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:type_of_care
|
focus on patient needs
|
|
gptkbp:website
|
www.medigene.com
|
|
gptkbp:bfsParent
|
gptkb:Sanofi
|
|
gptkbp:bfsLayer
|
4
|